Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20622007 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Fernandes MS, et al. (2010) Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem 285, 32596-605 20622007
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human) ▲
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor')
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease midostaurin
NAC decrease

Y371-p - Cbl (human) ▲
Orthologous residues
Cbl (human): Y371‑p, Cbl (mouse): Y369‑p, Cbl (rat): Y370‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor')
 Cellular systems studied:  cell lines
 Species studied:  mouse
Downstream Regulation
 Effect of modification (process):  apoptosis, altered, cell cycle regulation, cell growth, altered
Associated Diseases
Diseases: Alterations: Comments:
acute myelogenous leukemia mutation of site

Y674-p - Cbl (human) ▲
Orthologous residues
Cbl (human): Y674‑p, Cbl (mouse): Y672‑p, Cbl (rat): Y673‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor')
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease midostaurin

Y700-p - Cbl (human) ▲
Orthologous residues
Cbl (human): Y700‑p, Cbl (mouse): Y698‑p, Cbl (rat): Y699‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor')
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease midostaurin

Y774-p - Cbl (human) ▲
Orthologous residues
Cbl (human): Y774‑p, Cbl (mouse): Y780‑p, Cbl (rat): Y781‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor')
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease midostaurin

Y842-p - FLT3 (human) ▲
Orthologous residues
FLT3 (human): Y842‑p, FLT3 (mouse): Y845‑p, FLT3 iso3 (mouse): Y845‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor')
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease midostaurin
2-deoxyglucose decrease

Y955-p - FLT3 (human) ▲
Orthologous residues
FLT3 (human): Y955‑p, FLT3 (mouse): I958‑p, FLT3 iso3 (mouse): Y958‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor')
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease midostaurin
2-deoxyglucose decrease

Y969-p - FLT3 (human) ▲
Orthologous residues
FLT3 (human): Y969‑p, FLT3 (mouse): Q971‑p, FLT3 iso3 (mouse): Y972‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor')
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease midostaurin
2-deoxyglucose decrease

Y694-p - STAT5A (human) ▲
Orthologous residues
STAT5A (human): Y694‑p, STAT5A (mouse): Y694‑p, STAT5A iso2 (mouse): ‑, STAT5A (rat): Y694‑p, STAT5A (fruit fly): Y711‑p, STAT5A (sheep): Y694‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor')
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease midostaurin
NAC decrease


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.